Evidence map›Paper›PMID 40691644›Full record

ArticleJournal of eating disorders2025

Lived experiences of adolescents with anorexia nervosa and their parents during olanzapine treatment: a qualitative study.

Solène Thorey, Augustin Behaghel, Jordan Sibeoni, Corinne Blanchet, Marie Rose Moro, Emilie Carretier, Maude Ludot-Grégoire

Abstract read
In one paragraph

Article in Journal of eating disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Solène Thorey *Groupe ERIC, UPB Colibry, Centre Hospitalier de Plaisir, 30 Avenue Marc Laurent, 78370, Plaisir, France.
Augustin Behaghel *Service Universitaire de Psychiatrie de L'Adolescent, Argenteuil Hospital Centre, 69 Rue du Ltc Prud'hon, 95100, Argenteuil, France. augustinbehaghel@live.fr.
Jordan SibeoniService Universitaire de Psychiatrie de L'Adolescent, Argenteuil Hospital Centre, 69 Rue du Ltc Prud'hon, 95100, Argenteuil, France.
Corinne BlanchetMaison de Solenn-Maison Des Adolescents de Cochin (AP-HP), 97 Boulevard de Port-Royal, 75014, Paris, France.
Marie Rose MoroMaison de Solenn-Maison Des Adolescents de Cochin (AP-HP), 97 Boulevard de Port-Royal, 75014, Paris, France.
Emilie Carretier *CESP, UVSQ, Inserm, Université Paris-Sud, Université Paris-Saclay, Bâtiment 300, 91405, Orsay Cedex, France.
Maude Ludot-Grégoire *Maison de Solenn-Maison Des Adolescents de Cochin (AP-HP), 97 Boulevard de Port-Royal, 75014, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOlanzapine is commonly prescribed in Anorexia Nervosa, despite conflicting evidence regarding its efficacy and safety. This study aimed to complement existent quantitative by exploring the lived experiences of adolescents and parents with this treatment.

methodTen adolescent girls and ten parents were interviewed in a single psychiatric department in Paris. Data saturation was achieved. We used semi-structured interviews enriched with narrative methods, including writing tasks and picture elicitation questions.

resultsFour chronological meta-themes were identified: (1) Introduction of antipsychotic treatment with Olanzapine: rapid acceptance generating mixed feelings about the future. (2) The first few weeks of medication: Adolescents questioning alone the treatment after first intakes. (3) Taking note of the results during the initial few months of treatment. (4) Then what? Fears and doubts about the future.

conclusionThe prescription of olanzapine was often perceived as a liminal stage-a transitional moment akin to a "rite of passage" in the trajectory of Anorexia Nervosa. For many adolescents, it represented an opportunity to assert autonomy and gain a sense of empowerment in their relationships with both the medical team and their parents. However, implicit concerns about weight gain as a side effect often became a core issue of miscommunication. These concerns should be openly addressed throughout the treatment process. Shortening the usual duration of olanzapine therapy may offer a constructive path toward reinforcing the therapeutic alliance and avoiding non-medical discontinuation.

Indexed as

AdolescentsAnorexia nervosaAtypical antipsychoticsChild and adolescent psychiatryEating disordersNeurolepticsOlanzapineQualitative study

Identifiers

PMID40691644
PMCPMC12281770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.